1nessAgency
1nessAgency Insights
Healthcare digital marketing insights narrated by AI. Compliance strategy, patient acquisition, and AI optimization from 1nessAgency.
Be sure to visit the podcast's website and support the creator: www.1nessagency.com
Author
1nessAgency
Category
Podcast website
Latest episode
Nov 14, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Aetna's Insurance Gains Push CVS to Lift Annual Outlook 07.05.2026 16:00
CVS did not release granular Q1 2026 segment data at the time this article was prepared, but the company publicly raised its full-year guidance, a move that typically reflects management confidence in sustained margin improvement across its insurance, pharmacy, and care delivery businesses [1]. Aetn
White House Order Pushes FDA to Fast-Track Serious Mental Health Treatments 07.05.2026 15:00
The FDA's announcement names specific companies, specific compounds, and specific conditions. Three firms received national priority vouchers for psilocybin studies targeting treatment-resistant depression and major depressive disorder, and for methylone targeting PTSD [1]. DemeRx NB received cleara
Aetna's Insurance Gains Push CVS to Lift Annual Outlook 07.05.2026 16:00
CVS did not release granular Q1 2026 segment data at the time this article was prepared, but the company publicly raised its full-year guidance, a move that typically reflects management confidence in sustained margin improvement across its insurance, pharmacy, and care delivery businesses [1]. Aetn
White House Order Pushes FDA to Fast-Track Serious Mental Health Treatments 07.05.2026 15:00
The FDA's announcement names specific companies, specific compounds, and specific conditions. Three firms received national priority vouchers for psilocybin studies targeting treatment-resistant depression and major depressive disorder, and for methylone targeting PTSD [1]. DemeRx NB received cleara
FDA Clears First Gene Therapy For Rare Blood Disorder, Opening Door to New Treatment Class 27.04.2026 16:00
The FDA's March 26, 2026 approval of Kresladi (marnetegragene autotemcel) for severe Leukocyte Adhesion Deficiency Type I marks a turning point not just for pediatric immunology, but for how rare disease marketers must operate. Rocket Pharmaceuticals now holds the first-ever FDA-approved gene therap
Affordable Care Act Subsidy Lapse Erases 100,000 Patient Visits at Nation's Largest For-Profit Health System 27.04.2026 12:00
HCA Healthcare reported a $150 million revenue hit in Q1 2026 directly attributed to the lapse in Affordable Care Act subsidies, a figure that translates to roughly 100,000 patient visits at typical reimbursement rates. The nation's largest for-profit health system just quantified what most marketing
FDA Clears First Gene Therapy For Rare Blood Disorder, Opening Door to New Treatment Class 27.04.2026 16:00
The FDA's March 26, 2026 approval of Kresladi (marnetegragene autotemcel) for severe Leukocyte Adhesion Deficiency Type I marks a turning point not just for pediatric immunology, but for how rare disease marketers must operate. Rocket Pharmaceuticals now holds the first-ever FDA-approved gene therap
Affordable Care Act Subsidy Lapse Erases 100,000 Patient Visits at Nation's Largest For-Profit Health System 27.04.2026 12:00
HCA Healthcare reported a $150 million revenue hit in Q1 2026 directly attributed to the lapse in Affordable Care Act subsidies—a figure that translates to roughly 100,000 patient visits at typical reimbursement rates. The nation's largest for-profit health system just quantified what most marketing
FDA Unlocks Gene Therapy For Hearing Loss, Signaling Shift in Rare Disease Treatment 24.04.2026 15:00
The FDA just approved a gene therapy for genetic hearing loss in 61 days, tied for the fastest biologics license application approval in modern agency history. For healthcare marketers in the rare disease and precision medicine space, this velocity changes patient identification timelines, reimbursem
FDA Approves Psychedelic Drug Trials, Signaling Shift in Mental Health Treatment 24.04.2026 16:00
The FDA's decision in early 2026 to back three psychedelic drug studies for mental illness treatment marks the clearest regulatory signal yet that psychedelic-assisted therapy is on a trajectory toward mainstream clinical use , and healthcare systems that wait for full approval before building their
FDA Unlocks Gene Therapy For Hearing Loss, Signaling Shift in Rare Disease Treatment 24.04.2026 15:00
The FDA just approved a gene therapy for genetic hearing loss in 61 days—tied for the fastest biologics license application approval in modern agency history. For healthcare marketers in the rare disease and precision medicine space, this velocity changes patient identification timelines, reimbursem
FDA Approves Psychedelic Drug Trials, Signaling Shift in Mental Health Treatment 24.04.2026 16:00
The FDA's decision in early 2026 to back three psychedelic drug studies for mental illness treatment marks the clearest regulatory signal yet that psychedelic-assisted therapy is on a trajectory toward mainstream clinical use , and healthcare systems that wait for full approval before building their
UnitedHealth Hikes Profit Outlook After Better-Than-Expected First Quarter 22.04.2026 19:00
UnitedHealth Group raised its 2026 profit outlook following first-quarter earnings that exceeded Wall Street expectations, extending the nation's largest health insurer's financial outperformance at a moment when providers face margin pressure from real estate costs, regulatory compliance, and reimb
New CMS Rule Requires States to Audit Every Medicaid Provider in Sweeping Compliance Push 22.04.2026 15:00
CMS announced in 2026 its intent to require states to conduct audits of Medicaid-enrolled providers, according to reporting from Becker's Hospital Review [1]. While the regulatory machinery is still being assembled , state implementation timelines, audit scope, and enforcement thresholds remain subj
Biotech and Pharma Brace For Continued N.I.H. Funding Cuts in Second Trump Term 22.04.2026 14:00
The slowdown in National Institutes of Health grant awards accelerating into 2026 is doing more than shrinking research budgets , it is restructuring the competitive landscape for academic medical centers, community hospitals, and specialty practices that built patient acquisition strategies around
What Healthcare Marketers Need to Know About Ibogaine's Clinical Promise and Regulatory Path 22.04.2026 16:00
The most consequential psychedelic therapy conversation of 2026 is not about psilocybin or ketamine , it is about ibogaine, a Schedule I substance derived from the African iboga plant that is attracting serious federal attention for its potential to treat opioid use disorder (OUD). As the FDA naviga
UnitedHealth Hikes Profit Outlook After Better-Than-Expected First Quarter 22.04.2026 19:00
UnitedHealth Group raised its 2026 profit outlook following first-quarter earnings that exceeded Wall Street expectations, extending the nation's largest health insurer's financial outperformance at a moment when providers face margin pressure from real estate costs, regulatory compliance, and reimb
New CMS Rule Requires States to Audit Every Medicaid Provider in Sweeping Compliance Push 22.04.2026 15:00
CMS announced in 2026 its intent to require states to conduct audits of Medicaid-enrolled providers, according to reporting from Becker's Hospital Review [1]. While the regulatory machinery is still being assembled , state implementation timelines, audit scope, and enforcement thresholds remain subj
Biotech and Pharma Brace For Continued N.I.H. Funding Cuts in Second Trump Term 22.04.2026 14:00
The slowdown in National Institutes of Health grant awards accelerating into 2026 is doing more than shrinking research budgets , it is restructuring the competitive landscape for academic medical centers, community hospitals, and specialty practices that built patient acquisition strategies around
What Healthcare Marketers Need to Know About Ibogaine's Clinical Promise and Regulatory Path 22.04.2026 16:00
The most consequential psychedelic therapy conversation of 2026 is not about psilocybin or ketamine , it is about ibogaine, a Schedule I substance derived from the African iboga plant that is attracting serious federal attention for its potential to treat opioid use disorder (OUD). As the FDA naviga
FDA Takes Further Steps to Streamline Biosimilar Development and Make Medicines More Affordable 20.04.2026 17:00
The FDA's accelerated push to streamline biosimilar development and expand state drug importation programs in 2026 has opened a marketing opportunity most health systems haven't recognized: affordability messaging now belongs at the center of patient acquisition strategy, not buried in financial ass
Trump Signs Executive Order to Loosen Restrictions on Psychedelic Drugs 20.04.2026 18:00
A presidential executive order in April 2026 loosening restrictions on psychedelic drugs creates the first legitimate marketing opportunity for a substance class that has lived in regulatory limbo for half a century. Healthcare organizations and pharmaceutical companies now face a market with millio
FDA Takes Further Steps to Streamline Biosimilar Development and Make Medicines More Affordable 20.04.2026 17:00
The FDA's accelerated push to streamline biosimilar development and expand state drug importation programs in 2026 has opened a marketing opportunity most health systems haven't recognized: affordability messaging now belongs at the center of patient acquisition strategy, not buried in financial ass
Trump Signs Executive Order to Loosen Restrictions on Psychedelic Drugs 20.04.2026 18:00
A presidential executive order in April 2026 loosening restrictions on psychedelic drugs creates the first legitimate marketing opportunity for a substance class that has lived in regulatory limbo for half a century. Healthcare organizations and pharmaceutical companies now face a market with millio
Mark Cuban Wants to Bring Drug Manufacturing to Hospitals' Doorsteps, Literally 19.04.2026 17:00
Mark Cuban's push to place drug manufacturing facilities directly adjacent to hospitals represents the most significant threat to traditional pharmaceutical marketing relationships since the 340B pricing debate erupted. When the intermediary between manufacturer and patient collapses to zero distanc
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.